Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Nisha Unni, Dhivya R. Sudhan, Carlos L. Arteaga

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.

Original languageEnglish (US)
Pages (from-to)3483-3485
Number of pages3
JournalClinical Cancer Research
Volume24
Issue number15
DOIs
StatePublished - Aug 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neratinib: Inching up on the cure rate of HER2<sup>+</sup> breast cancer?'. Together they form a unique fingerprint.

Cite this